Regeneron reported a strong Q3 2020 with a 32% increase in revenue to $2.29 billion. GAAP diluted EPS was $7.39 and non-GAAP diluted EPS was $8.36. Key developments included positive results for REGN-COV2 in COVID-19 outpatients and FDA acceptance for priority review of Libtayo for advanced non-small cell lung cancer and basal cell carcinoma.
Third quarter 2020 revenues increased 32% to $2.29 billion versus third quarter 2019
Third quarter 2020 EYLEA® U.S. net sales increased 11% to $1.32 billion versus third quarter 2019
Third quarter 2020 Dupixent® global net sales increased 69% to $1.07 billion versus third quarter 2019
Third quarter 2020 GAAP diluted EPS was $7.39 and non-GAAP diluted EPS was $8.36
Regeneron provided full year 2020 financial guidance which includes GAAP and Non-GAAP estimates for R&D, SG&A, COGS, COCM, Other operating (income) expense, net, Capital expenditures, and Effective tax rate (ETR).
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance